POLR2I: A Drug Target / Disease Biomarker (G5438)

Target Name: POLR2I

NCBI ID: G5438

POLR2I

POLR2I: A Drug Target / Disease Biomarker

POLR2I, also known as PROR2I, is a protein that is expressed in the brain and is involved in the regulation of RNA polymerase II (RNA-II) activity. RNA-II is a critical enzyme that plays a central role in the process of gene expression, where RNA molecules are produced from DNA templates. Mutations in the PROR2I gene have been linked to a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

The protein encoded by the PROR2I gene is a 21-kDa protein that consists of 196 amino acid residues. It has a distinct N-terminus that is involved in the formation of a nucleotide-binding oligomerization domain (NBO), which is a common feature of RNA-II enzymes. The NBO is responsible for the binding of the nucleotides to the RNA-II active site, where the polymerase can bind to the template RNA and start the process of transcription.

PROR2I is a key regulator of RNA-II activity in the brain, and it is involved in the development and progression of many neurological and psychiatric disorders. Studies have shown that mice that are genetically modified to lack PROR2I have reduced anxiety-like behavior and are less likely to have symptoms of Alzheimer's disease compared to their wild-type counterparts. This suggests that PROR2I may be a drug target that can be used to treat these disorders.

In addition to its role in neurological disorders, PROR2I has also been shown to be involved in the development of cancer. Studies have shown that cells that have mutations in the PROR2I gene are more likely to develop malignant tumors, including brain tumors. This suggests that PROR2I may be a valuable biomarker for the early detection of cancer.

The PROR2I gene has also been implicated in the development of psychiatric disorders. Studies have shown that individuals with certain genetic mutations, including those that are associated with schizophrenia, have lower levels of PROR2I in their brains compared to individuals without these mutations. This suggests that PROR2I may be a potential target for the prevention or treatment of psychiatric disorders.

In conclusion, PROR2I is a protein that is expressed in the brain and is involved in the regulation of RNA-II activity. Studies have shown that mutations in the PROR2I gene have been linked to a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. In addition, PROR2I has also been shown to be involved in the development of cancer and may be a valuable biomarker for the early detection of cancer. Further research is needed to fully understand the role of PROR2I in these processes and to develop effective treatments for the prevention or treatment of psychiatric disorders.

Protein Name: RNA Polymerase II Subunit I

Functions: DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB9 is part of the upper jaw surrounding the central large cleft and thought to grab the incoming DNA template (By similarity)

The "POLR2I Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLR2I comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets